Imatinib to change triple-negative breast cancer to ER-positive
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether imatinib (a pill medicine) can “convert” triple-negative breast cancer into an ER-positive type, which may change how the cancer behaves. If the conversion happens, it could open the door to more treatment options in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older.
- Your breast cancer is invasive triple-negative, and its ER, PR, and HER2 tests are all negative.
- You have not had any previous medicine treatments (chemo or other anti-cancer drugs) for triple-negative breast cancer.
- You’re not planning other cancer treatments at the same time (except bone-strengthening shots like bisphosphonates).
- Your general strength is good (ECOG 0–1), and blood tests and liver/kidney tests are within required ranges.
- You can swallow an oral medication and you can follow study visits and sign consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This trial tests a combination of an immunotherapy (camrelizumab), an anti-fibrotic drug (pirfenidone), and standard chemotherapy for people with advanced triple-negative breast cancer that has not gotten worse after initial treatment. The goal is to see if this mix works better than chemo alone.
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
This trial tests whether using a blood test to detect leftover cancer DNA after initial treatment can help doctors decide if extra therapy is needed for people with early triple-negative breast cancer. It aims to improve outcomes for those with remaining disease after neoadjuvant therapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.